{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T19:53:19Z","timestamp":1789501999869,"version":"build-2803163510"},"reference-count":41,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>\n                      This study examined the impact of glutathione-\n                      <jats:italic toggle=\"yes\">S<\/jats:italic>\n                      -transferase polymorphisms (GSTA1, GSTM1, GSTP1, and GSTT1) on the area under the curve (AUC), clearance, veno-occlusive disease (VOD), and graft-versus-host disease (GvHD) in hematopoietic stem cell transplant (HSCT) patients treated with intravenous busulfan.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic review was performed on three electronic databases to identify relevant studies. The relative risk and the 95% confidence interval (CI) of the association of different GST polymorphisms with pharmacokinetic and clinical outcomes were reported using the random and fixed effect models. Quality of the studies was assessed using the Newcastle\u2013Ottawa Scale for cohort studies. Heterogeneity between studies and publication bias were also carried out using R software.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Eighteen studies were included in the meta-analysis. GSTA1*A\/*B was significantly associated with lower clearance (95% CI: 0.008\u20131.223,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.048) and higher AUC (95% CI: \u2212374.960 to \u201356.661,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.008) than the GSTA1*A\/*A genotype. GSTA1*B\/*B had a higher busulfan AUC than GSTA1*A\/*A (95% CI: \u2212403.531 to \u221289.454,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.002). None of the other genotypes was significantly associated with busulfan pharmacokinetic parameters or the risk of VOD or GvHD.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>GSTA1 should be considered as a guide for intravenous busulfan dosing in allogeneic HSCT patients, where patients with the GSTA1*A\/*A genotype require a higher dose than GSTA1*B carriers.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/fpc.0000000000000589","type":"journal-article","created":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T22:00:24Z","timestamp":1765836024000},"page":"32-47","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Effects of glutathione-S-transferase polymorphisms on intravenous busulfan in hematopoietic stem cell transplant patients: a meta-analysis"],"prefix":"10.1097","volume":"36","author":[{"given":"Bushra","family":"Salman","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Sultan Taboos University Hospital, University Medical City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Intisar","family":"Al Riyami","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Sultan Taboos University Hospital, University Medical City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raya","family":"Al Maskari","sequence":"additional","affiliation":[{"name":"Pharmacology and Clinical Pharmacy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murtadha","family":"Al Khabori","sequence":"additional","affiliation":[{"name":"Hematology, College of Medicine and Health Sciences, Sultan Qaboos University, Al Khoudh, Oman"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,12,9]]},"reference":[{"key":"R1-20260128","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1007\/s12185-020-02891-0","article-title":"Busulfan clearance does not predict the development of hepatic veno-occlusive disease in patients undergoing hematopoietic stem cell transplantation.","volume":"112","author":"Salman","year":"2020","journal-title":"Int J Hematol"},{"key":"R2-20260128","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1016\/j.bbmt.2017.07.022","article-title":"GSTA1 genetic variants and conditioning regimen: missing key factors in dosing guidelines of busulfan in pediatric hematopoietic stem cell transplantation.","volume":"23","author":"Nava","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"R3-20260128","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1002\/pbc.25376","article-title":"New insights into the pharmacokinetics of intravenous busulfan in children with sickle cell anemia undergoing bone marrow transplantation.","volume":"62","author":"Gaziev","year":"2015","journal-title":"Pediatr Blood Cancer"},{"key":"R4-20260128","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1007\/s12185-019-02741-8","article-title":"Analysis of glutathione S-transferase and cytochrome P450 gene polymorphism in recipients of dose-adjusted busulfan-cyclophosphamide conditioning.","volume":"111","author":"Terakura","year":"2020","journal-title":"Int J Hematol"},{"key":"R5-20260128","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/S0090-9556(25)07498-7","article-title":"Busulfan conjugation by glutathione S-transferases alpha, mu, and pi.","volume":"24","author":"Czerwinski","year":"1996","journal-title":"Drug Metab Dispos"},{"key":"R6-20260128","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1002\/pbc.22739","article-title":"Influence of glutathione S-transferase A1, P1, M1, T1 polymorphisms on oral busulfan pharmacokinetics in children with congenital hemoglobinopathies undergoing hematopoietic stem cell transplantation.","volume":"55","author":"Elhasid","year":"2010","journal-title":"Pediatr Blood Cancer"},{"key":"R7-20260128","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1080\/17425255.2017.1360277","article-title":"Clarifying busulfan metabolism and drug interactions to support new therapeutic drug monitoring strategies: a comprehensive review.","volume":"13","author":"Myers","year":"2017","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"R8-20260128","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s40262-020-00947-2","article-title":"Review of the pharmacokinetics and pharmacodynamics of intravenous busulfan in paediatric patients.","volume":"60","author":"Lawson","year":"2021","journal-title":"Clin Pharmacokinet"},{"key":"R9-20260128","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1097\/FTD.0000000000000180","article-title":"Glutathione transferase gene variants influence busulfan pharmacokinetics and outcome after myeloablative conditioning.","volume":"37","author":"Bremer","year":"2015","journal-title":"Ther Drug Monit"},{"key":"R10-20260128","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1177\/0091270010382915","article-title":"Pharmacogenetics of intravenous and oral busulfan in hematopoietic cell transplant recipients.","volume":"51","author":"Abbasi","year":"2011","journal-title":"J Clin Pharmacol"},{"key":"R11-20260128","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1111\/bcpt.13185","article-title":"Effect of glutathione S-transferase genetic polymorphisms on busulfan pharmacokinetics and veno-occlusive disease in hematopoietic stem cell transplantation: a meta-analysis.","volume":"124","author":"Kim","year":"2019","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"R12-20260128","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"R14-20260128","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1471-2288-5-13","article-title":"Estimating the mean and variance from the median, range, and the size of a sample.","volume":"5","author":"Hozo","year":"2005","journal-title":"BMC Med Res Methodol"},{"key":"R15-20260128","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/bmt.2009.143","article-title":"Influence of GST gene polymorphisms on busulfan pharmacokinetics in children.","volume":"45","author":"Ansari","year":"2010","journal-title":"Bone Marrow Transplant"},{"key":"R16-20260128","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.2217\/pgs.15.98","article-title":"Population pharmacokinetics and pharmacodynamics of busulfan with GSTA1 polymorphisms in patients undergoing allogeneic hematopoietic stem cell transplantation.","volume":"16","author":"Choi","year":"2015","journal-title":"Pharmacogenomics"},{"key":"R17-20260128","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/j.bbmt.2010.12.708","article-title":"Influence of GST gene polymorphisms on the clearance of intravenous busulfan in adult patients undergoing hematopoietic cell transplantation.","volume":"17","author":"Kim","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"R18-20260128","doi-asserted-by":"crossref","first-page":"401","DOI":"10.3390\/pharmaceutics14020401","article-title":"Effect of GSTA1 variants on busulfan-based conditioning regimen prior to allogenic hematopoietic stem-cell transplantation in pediatric asians.","volume":"14","author":"Nguyen","year":"2022","journal-title":"Pharmaceutics"},{"key":"R19-20260128","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/ped.13859","article-title":"Influence of GST polymorphisms on busulfan pharmacokinetics in Japanese children.","volume":"61","author":"Nishikawa","year":"2019","journal-title":"Pediatr Int"},{"key":"R20-20260128","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1038\/s41409-023-01963-z","article-title":"Effect of pharmacokinetics and pharmacogenomics in adults with allogeneic hematopoietic cell transplantation conditioned with busulfan.","volume":"58","author":"Seydoux","year":"2023","journal-title":"Bone Marrow Transplant"},{"key":"R21-20260128","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.2217\/pgs.13.159","article-title":"Effect of genetic variants GSTA1 and CYP39A1 and age on busulfan clearance in pediatric patients undergoing hematopoietic stem cell transplantation.","volume":"14","author":"Ten Brink","year":"2013","journal-title":"Pharmacogenomics"},{"key":"R22-20260128","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/j.1399-0012.2006.00624.x","article-title":"Glutathione S-transferase A1 polymorphisms and acute graft-vs.-host disease in HLA-matched sibling allogeneic hematopoietic stem cell transplantation.","volume":"21","author":"Kim","year":"2007","journal-title":"Clin Transplant"},{"key":"R23-20260128","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1038\/bmt.2015.14","article-title":"Once-daily i.v. BU-based conditioning regimen before allogeneic hematopoietic SCT: a study of influence of GST gene polymorphisms on BU pharmacokinetics and clinical outcomes in Chinese patients.","volume":"50","author":"Yin","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"R24-20260128","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1038\/bmt.2012.265","article-title":"Glutathione S-transferase gene variations influence BU pharmacokinetics and outcome of hematopoietic SCT in pediatric patients.","volume":"48","author":"Ansari","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"R25-20260128","doi-asserted-by":"crossref","first-page":"90852","DOI":"10.18632\/oncotarget.20310","article-title":"GSTA1 diplotypes affect busulfan clearance and toxicity in children undergoing allogeneic hematopoietic stem cell transplantation: a multicenter study.","volume":"8","author":"Ansari","year":"2017","journal-title":"Oncotarget"},{"key":"R26-20260128","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1177\/0091270008321940","article-title":"Glutathione S-transferase A1 genetic variants reduce busulfan clearance in children undergoing hematopoietic cell transplantation.","volume":"48","author":"Johnson","year":"2008","journal-title":"J Clin Pharmacol"},{"key":"R27-20260128","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/bmt.2011.55","article-title":"Effect of genetic polymorphisms in genes encoding GST isoenzymes on BU pharmacokinetics in adult patients undergoing hematopoietic SCT.","volume":"47","author":"ten Brink","year":"2012","journal-title":"Bone Marrow Transplant"},{"key":"R28-20260128","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1097\/FPC.0000000000000007","article-title":"Exploratory analysis of 1936 SNPs in ADME genes for association with busulfan clearance in adult hematopoietic stem cell recipients.","volume":"23","author":"Ten Brink","year":"2013","journal-title":"Pharmacogenet Genomics"},{"key":"R29-20260128","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1097\/FTD.0000000000000957","article-title":"Impact of glutathione S-transferase polymorphisms on busulfan pharmacokinetics and outcomes of hematopoietic stem cell transplantation.","volume":"44","author":"Al-Riyami","year":"2022","journal-title":"Ther Drug Monit"},{"key":"R30-20260128","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1159\/000028396","article-title":"Glutathione S-transferase polymorphisms and their biological consequences.","volume":"61","author":"Hayes","year":"2000","journal-title":"Pharmacology"},{"key":"R31-20260128","doi-asserted-by":"crossref","first-page":"e14364","DOI":"10.1111\/ctr.14364","article-title":"Genetic polymorphisms of cytotoxic T-lymphocyte antigen 4 (CTLA-4) and clinical outcomes post-allogeneic hematopoietic stem cell transplantation: a systematic review and meta-analysis.","volume":"35","author":"Najafi","year":"2021","journal-title":"Clin Transplant"},{"key":"R32-20260128","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.jtct.2022.01.013","article-title":"Association between the magnitude of intravenous busulfan exposure and development of hepatic veno-occlusive disease in children and young adults undergoing myeloablative allogeneic hematopoietic cell transplantation.","volume":"28","author":"Bogn\u00e0r","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"R33-20260128","doi-asserted-by":"crossref","first-page":"332.e1","DOI":"10.1016\/j.jtct.2023.12.003","article-title":"Pharmacokinetic modeling and simulation with pharmacogenetic insights support the relevance of therapeutic drug monitoring for myeloablative busulfan dosing in adult HSCT.","volume":"30","author":"Ben Hassine","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"R34-20260128","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1097\/00008571-200206000-00003","article-title":"The human glutathione transferase alpha locus: genomic organization of the gene cluster and functional characterization of the genetic polymorphism in the hGSTA1 promoter.","volume":"12","author":"Morel","year":"2002","journal-title":"Pharmacogenetics"},{"key":"R35-20260128","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1002\/hep.22922","article-title":"Glutathione S-transferase M1 and T1 null genotypes increase susceptibility to drug-induced liver injury#.","volume":"49","author":"Lucena","year":"2009","journal-title":"Hepatology"},{"key":"R36-20260128","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s00432-021-03677-5","article-title":"Association of recipient and donor interleukin 6 polymorphisms 174 and 597 with outcome after allogeneic hematopoietic stem cell transplantation in children.","volume":"148","author":"Wetzel","year":"2022","journal-title":"J Cancer Res Clin Oncol"},{"key":"R37-20260128","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/j.bbmt.2019.02.018","article-title":"Risk factors for development of and progression of hepatic veno-occlusive disease\/sinusoidal obstruction syndrome.","volume":"25","author":"Corbacioglu","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"R38-20260128","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1182\/blood-2003-11-3778","article-title":"Glutathione S-transferase M1 polymorphism: a risk factor for hepatic venoocclusive disease in bone marrow transplantation.","volume":"104","author":"Srivastava","year":"2004","journal-title":"Blood"},{"key":"R39-20260128","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.bbmt.2018.07.039","article-title":"Early clinical predictors of hepatic veno-occlusive disease\/sinusoidal obstruction syndrome after myeloablative stem cell transplantation.","volume":"25","author":"Roeker","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"R40-20260128","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1038\/s41409-021-01215-y","article-title":"Incidence and risk factors of hepatic veno-occlusive disease\/sinusoidal obstruction syndrome after allogeneic hematopoietic cell transplantation in adults with prophylactic ursodiol and intravenous heparin or prostaglandin E1.","volume":"56","author":"Yoon","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"R41-20260128","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1399-0004.1998.tb04286.x","article-title":"Prevalence of homozygosity for the deleted alleles of glutathione S-transferase mu (GSTM1) and theta (GSTT1) among distinct ethnic groups from Brazil: relevance to environmental carcinogenesis?","volume":"54","author":"Arruda","year":"1998","journal-title":"Clin Genet"},{"key":"R42-20260128","doi-asserted-by":"crossref","first-page":"101313","DOI":"10.1016\/j.genrep.2021.101313","article-title":"Frequency of glutathione S-Transferase M1, T1 and P1 genotypes and their combinations in northern West Bengal, India: implications for disease association.","volume":"25","author":"Dutta","year":"2021","journal-title":"Gene Rep"}],"container-title":["Pharmacogenetics and Genomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FPC.0000000000000589","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T19:00:26Z","timestamp":1769626826000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FPC.0000000000000589"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,9]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/fpc.0000000000000589","relation":{},"ISSN":["1744-6872","1744-6880"],"issn-type":[{"value":"1744-6872","type":"print"},{"value":"1744-6880","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,9]]},"assertion":[{"value":"2025-03-15","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-12","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}